Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.78)
# 109
Out of 5,134 analysts
41
Total ratings
68.75%
Success rate
36.34%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRXS NeurAxis | Maintains: Buy | $7 → $8 | $5.39 | +48.42% | 2 | Dec 22, 2025 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $50.54 | +26.63% | 4 | Sep 23, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $8.73 | +60.37% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.41 | +194.78% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $6.91 | +59.19% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $8.70 | +26.44% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.04 | -1.32% | 1 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $12.76 | +33.23% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $17.15 | +63.27% | 6 | May 14, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $17.72 | +120.09% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.78 | +67.36% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $9.40 | +123.40% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.67 | +28.48% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $5.16 | +132.56% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $7.99 | +25.19% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.59 | +103.22% | 2 | Jul 11, 2023 |
NeurAxis
Dec 22, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $5.39
Upside: +48.42%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $50.54
Upside: +26.63%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $8.73
Upside: +60.37%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.41
Upside: +194.78%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $6.91
Upside: +59.19%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $8.70
Upside: +26.44%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.04
Upside: -1.32%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $12.76
Upside: +33.23%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $17.15
Upside: +63.27%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $17.72
Upside: +120.09%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.78
Upside: +67.36%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $9.40
Upside: +123.40%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.67
Upside: +28.48%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $5.16
Upside: +132.56%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $7.99
Upside: +25.19%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.59
Upside: +103.22%